[Pharmacological treatments for obesity : what does the future hold?]

Abstract

Recent pharmacological advances, illustrated by molecules such as semaglutide 2,4 mg and tirzepatide, have transformed the management of obesity. New innovative molecules, based in particular on key entero-pancreatic hormones such as glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, glucagon, and amylin, are currently being studied as monotherapies or in various combinations. Other therapies targeting other pathways, such as the leptin-melanocortin pathway, are also in development. Initial results regarding weight loss are promising, but long-term studies are needed to assess their safety and lasting efficacy. These medications must be part of an overall management approach in which lifestyle changes remain essential to ensure lasting, optimal results.